The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

COVID paused prevention efforts, which helped fuel the rise in new infections. Now federal funding cuts threaten to disrupt ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

U.S. withdrawal of $4 billion in AIDS funding risks over 4 million deaths and 6 million new HIV infections by 2029 ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were ...

Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...